inc buy pt data point lead us conclud recent momentum due hybrid cloud data
manag capabl dell mis-execut analyst nehal chokshi full summari
 sell pt earn review bad expect still sizabl loss
contravir pharmaceut inc ctrv buy pt txl pathway news analyst jason
vivev medic inc vive buy pt capit rais support vivev ii studi posit pilot studi technolog
treatment stress urinari incontin analyst anthoni vendetti full summari
corpor event call maxim salesperson inform
landec corpor cover vendetti ndr boston cfo greg skinner tue feb
dineequ inc cover ndr san francisco ceo stephen joyc interim cfo gregori
kalvin execut director ir ken dipte mon feb
cover ndr boston cfo golder wed jun
moviepass/helio matheson analyt inc hmni cover kinstling institut group lunch nyc
moviepass ceo mitch low helio ceo ted famsworth tue feb
keyw hold corp keyw cover kinstling ndr san francisco ceo weber wed thu feb
nic inc cover kinstling ndr nyc cfo steve kovzan vice-president corpor commun
corp cover kinstling ndr boston cfo ranjan kalia wed
data point lead us conclud recent momentum due
hybrid cloud data manag capabl dell
mis-execut emc integr appear sourc
data point indic momentum due uniqu
effect hybrid cloud data manag capabl
ahead ep due tomorrow post-clos rais outyear
estim modestli dcf-base price target
mis-execut emc integr appear sourc
turnaround sinc januari report product revenu
growth averag per year revers prior quarter trend averag
y/i declin share outperform sinc
last earn report manag provid guidanc triangul
impli product revenu januari april quarter grow
y/i similar octob quarter level convers investor
indic belief recent momentum due dell mis-execut
integr emc close septemb time-frame observ
inflect product revenu y/i growth elev investor concern
ntap turnaround short-liv manag commun
understand integr privat emc storag sale
gone plan storag revenu mid-singl digit server revenu
y/i compani taken correct action hire storag
specialist past month though manag caution
take year new invest yield benefit
data point indic momentum due uniqu
effect hybrid cloud data manag capabl
replic investor concern logic channel check indic
mis-execut dell integr emc coincident correl ntap
turnaround rather actual caus specif channel check indic
win deal hybrid cloud data manag capabl
embodi singular oper system uniqu compel also
mesh manag explan driver momentum
host manag ndr januari manag also note
uniqu enabl sale forc extend relationship further-up
decision-mak chain within organ note uniqu
ntap hybrid cloud data manag capabl eman singular
oper system data ontap except solidfir select afa case
altavault draa combin emc storag portfolio
yet simplifi believ least nine uniqu oper system
base convers manag believ
simplifi look develop next gener all-encompass storag
oper system integr tool like vipr suppos repres
went gener avail septemb note august upgrad
develop portfolio hybrid cloud data manag product
larg underpin data ontap includ netapp privat storag releas
late ontap cloud launch late altavault acquir
cloudsync cloud control releas late product form
effect complet hybrid cloud data manag capabl span mission
critic workload burst privat public cloud np basic
rais outyear estim modestli dcf-base price target
rais product revenu growth rate
low-singl digit growth rate guidanc manag provid
april analyst day given data point indic ntap momentum
due uniqu like sustain uniqu ntap hybrid cloud data
manag product suit underpin data ontap also increas
confid thesi laid august upgrad well posit
continu expand oper margin high end
om guidanc consensu maxim rais
price target remain base dcf basi reflect acquisit
adjust assum util acquisit consist prior five-year
averag termin period also drive chang defer
revenu zero ensur equilibr non-gaap net incom addit
increas revenu margin estim also give credit
reduc rate sbce ltm vs past year tax reform
enabl repatri oversea cash gross cash assum
debt-to-equ result key paramet input chang
dcf discount rate effect discount rate discount rate
rais price target
click full note
capit rais support vivev ii studi posit pilot
studi technolog treatment stress urinari
today vive complet public offer share per
share believ net capit rais suffici fund compani
end
compani announc posit result pilot trial studi cryogen-
cool monopolar radiofrequ cmrf technolog treatment
vive plan conduct two clinic trial pursuit fda health canada
ce mark approv devic temporari improv mild-to-
bottom line would continu buyer vive equiti offer
believ provid suffici capit fund pivot vivev ii studi
expect commenc opinion potenti gain expand
fda approv improv femal sexual function addit current
indic electrocoagul hemostasi repres import
growth opportun compani addit also encourag posit
result compani studi technolog non-invas treatment
stress urinari incontin believ repres addit
entri januari vive announc result pilot studi
cmrf technolog treatment month
nine patient complet protocol show improv compar
baselin mean improv across two endpoint
respect device-rel safeti issu report base posit
result vive intend conduct two addit trial includ
liber us random double-blind sham-control studi us
site enrol patient suffer mild-to-moder
liber random double-blind sham-control studi
site canada enrol patient suffer mild-to-
vive plan submit investig devic exempt fda
intend pursu regulatori approv us canada ce mark
public offer today vive complet public offer share
per share net proce roughli includ full exercis
share underwrit option proce expect use support research
develop effort includ commenc pivot vivev ii trial
well product commerci
revis estim due issuanc share public offer
narrow loss per share estim
respect
attract valuat due compani progress later stage fda
regulatori pathway continu commerci success lower
year dcf discount rate maintain termin growth rate
off-set equiti dilut result public offer result
maintain pt vive current trade ev/revenu estim
compar peer averag price target impli share trade
ev/revenu estim believ justifi due compani
defens technolog posit signific growth potenti
click full note
txl pathway news
fda agre manag note press releas today
receiv final written minut meet fda januari
summar outcom meet feedback receiv highlight
meet includ
agreement abbrevi non-clin develop program
agreement clinic pharmacolog packag
agreement major element phase trial design treatment-
nave patient chronic hepat hbeag heag includ
durat treatment clinic endpoint compar
agreement number patient safeti databas need nda
conclus save time money marketplac see txl
viabl altern gilead buy viread
previous discuss part hing door strategi mean could
backbon regimen hbv combin offer altern viread
contravir recent announc posit result phase pk trial new
txl formul studi includ healthi patient sever
impair renal function found safe well-toler group
pk analysi patient given txl found produc blood level
tenofovir equival viread current standard care indic
dose strength adjust necessari patient compromis
remind txl prodrug tenofovir viread txl design offer
equal better hbv viral load reduct dose lower viread tdf new
formul introduc compani receiv dsmb clearanc decemb
dose escal formul design
enhanc optim oral deliveri txl sinc time txl establish
excel safeti efficaci profil recal prior phase trial evalu
effect multipl ascend oral dose txl mg proof-
of-concept poc trial data demonstr txl dose test result
substanti lower system circul level tenofovir blood compar
viread new formul design enhanc optim oral deliveri
txl mechan action driven uniqu chemistri molecul
lipid moieti allow better intracellular convers hdp-tenofovir tenofovir
proven pro-drug chemistri lipid conjug effici adsorb cleav
like convent drug convert activ compound insid cell txl uniqu
concentr antivir activ tenofovir liver enabl anti-hbv efficaci
lower dose minim system drug exposur txl time activ base
vitro conclus
given pro-drug natur txl believ high probabl
success lower better safeti efficaci treatment hbv txl
part hing door strategi mean could backbon regimen
hbv combin offer altern viread compani plan
leverag tfv databas specif pathway fast approv
commerci given pro-drug natur txl believ high
probabl success lower better safeti efficaci treatment hbv
click full note
earn review bad expect still
report result ahead estim
consensu forecast remain depress beat mainli
attribut higher tce rate per vessel/day versu estim
per vessel/day
wonder compani decid includ three newbuild vessel
show report lower fleet-ag profil vessel age import
state compani prior report addit report fleet age
year calcul incorrect trade fleet year old
past modern vessel distinct
state sale leaseback transact ocean yield asa
attract term howev base forecast current
market environ view transact drain cash
reserv pleas see everyth kitchen sink note publish
decemb
result stronger remain depress loss
report morn revenu million ebitda million
oper loss surprisingli stronger expect lower
consensu estim forecast revenu million ebitda
million oper loss versu consensu estim top-
line revenu million ebitda million oper loss
estim beat due higher report tce rate per vessel/
day versu estim per vessel/day
catalyst forecast period fail see catalyst share
rebound forecast period demonstr vintag fleet
incap compet newer trade suezmax vessel offer higher fuel
effici lower oper cost well abil trade freeli port
allow higher util addit newbuild suezmax vessel
schedul enter fleet expect could place downward
pressur abil earn market rate
rais estim primarili bearish tce rate
revis util spot earn expect
revenu million million prior ebitda million million prior
oper loss loss figur base
updat tce rate per vessel/day per vessel/day prior
note week end februari global suezmax fleet earn
averag spot rate per vessel/day modern tonnag
per vessel/day vintag tonnag
valuat see bullish indic near- medium-term
recommend investor reduc posit believ global crude trade market
yet settl due opec product cut increas north american crude
product dynam led transit period trade rout expect
begin normal howev grow north american crude export
opinion catalyst event could particip due vintag
natur vessel therefor reiter sell rate price target
price target base multipl forward normal
prior believ discount warrant due older age profil
fleet
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
